By further exploring the mechanism, our previous work suggested that IL-6 was associated with sorafenib-induced tumor invasiveness but only through IL-6, and its subsequent signaling pathways such as PI3K/JAK/STAT may not fully explain the time and dosage-specific effects of sorafenib on HCC cells. This evidence concerns the gene IL6 and hepatocellular carcinoma.